PARIS--(BUSINESS WIRE)--Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible for PEA-PME savings schemes in France), the pioneer in 2D/3D orthopaedic medical imaging, today announced its consolidated revenue for the first quarter ended March 31, 2017.
Marie Meynadier, Chief Executive Officer of EOS imaging, said, “We delivered a quarter of strong growth, building on our positive momentum in EMEA, including a first sale in Israel and significant sales in the United Kingdom. This also reflects an excellent momentum in the Asia-Pacific region, driven by market approval in China obtained in 2016.”
|€ millions||Q1 2017||Q1 2016|
|As a % of total revenues||77%||77%|
|Sales of maintenance||1.40||0.99|
|As a % of total revenues||19%||18%|
|Sales of consumables and services||0.26||0.24|
|As a % of total revenues||4%||5%|
- First-quarter 2017 revenue up 34% to €7.13 million
The Company sold 14 EOS® platforms in the first quarter of 2017, compared to 10 in the same period last year. Revenues from sales of equipment totalled €5.47 million, an increase of 34%.
Sales of maintenance contracts increased by 41% to €1.40 million against €0.99 million in the first quarter of 2015. This reflects the continued increase in the installed base of EOS systems and an associated high contract subscription rate after warranty.
Sales of consumables and services were €0.26 million in the first quarter of 2017 versus €.024 million in the first quarter of 2016.
- The strong growth in sales was driven by continued expansion in EMEA and Asia-Pacific
|€ millions||Q1 2017||Q1 2016|
EOS reported continued sales momentum in EMEA, generating revenue of €3.21 million, an increase of 31% compared to the same period last year. This included strong sales in the United Kingdom as well as a first sale in Israel.
Sales in North America were €2.48 million, a decrease of 13% compared to the first quarter of 2016, which included particularly high sales in this region.
Sales in the Asia-Pacific region were €1.44 million. This largely reflects sales in China following regulatory approval in 2016.
- Chief Financial Officer Transition
Anne Renevot, EOS imaging’s Chief Financial Officer, will leave the Company at the end of April to pursue other professional interests. The EOS imaging financial team, composed of 5 employees, will be led by an interim-CFO until the recruitment of a permanent CFO is completed. "I would like to thank Anne for her professionalism, commitment and contribution to the development of the Company. I wish her as much success in her new career as she had in our collaboration," said Marie Meynadier.
For more information, please visit www.eos-imaging.com.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
About EOS imaging
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2016 revenues of €30.8 million and employs 132 people at December 2016, including an R&D team of 43 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.
Next press release: 2017 First-half sales on July 18, 2017 (after the market close)